MOVErs from DSEV
List of MOVE fellowship awardees (MOVErs)
Affiliation
PhD student Department of Molecular Medicine
MOVE host lab
Dr. Oscar Wiklander
Karolinska Institute, Department of Laboratory Medicine
Sweden
Grant amount and period of the research stay
DKK 15.000 for 3 months (Oct 2026 – Dec 2026)
EV techniques
EV engineering, EV isolation from breast cancer cell lines, Flow cytometry analysis of tumor microenvironment, In vivo EV tracking
Project title
Unravelling the Crosstalk between Tumor-Derived Extracellular Vesicles and the Tumor Microenvironment
Project in a nutshell
The project addresses a timely question in extracellular vesicle (EV) research: how tumor-derived EVs shape the immunosuppressive tumor microenvironment that drives therapy resistance in ER+ breast cancer. During my stay, I will generate and use fluorescently tagged EV-reporter breast cancer cell lines to determine which immune cell populations take up tumor-derived EVs, which EV subtypes mediate this signaling, and how these EVs interact with the microenvironment. This work can advance our understanding of EV-mediated immune modulation and reveal new strategies for overcoming therapy resistance.
Affiliation
Postdoc
Department of Animal and Veterinary Sciences
MOVE host lab
Prof. Alireza Fazeli and Dr. Suranga Kodithuwakku
University of Tartu, Institute of Biomedicine and Translational Medicine
Estonian University of Life Sciences, Institute of Veterinary Medicine and Animal Sciences
Estonia
Grant amount and period of the research stay
DKK 15.000 for 2 months (Oct 2025 – Nov 2025)
EV techniques
EV isolation, upscaling and characterization from parasite vesicles
Project title
EV isolation and upscaling from helminths, host-cells and host feces
Project in a nutshell
EVs from Ascaridia galli are considered promising vaccine candidates, but their development is currently constrained by insufficient characterization and limited large-scale production. In this project, deep characterization and upscaling of A. galli EV production are pursued using combined differential centrifugation and size exclusion chromatography to improve EV yield, purity, and biological integrity. Isolation of EVs from fecal samples is also addressed, building on protocols developed by the host group and enabling analysis of parasite- and host-derived EVs under natural infection conditions. Access to the advanced EV isolation expertise and standardized methodologies available in Tartu is therefore considered essential to overcome current bottlenecks, enable antigen discovery, and support future comparative EV analyses across parasites and host systems.